Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its current reports, financial updates, and material event announcements. These documents offer detailed insight into how Crinetics manages its endocrine-focused pharmaceutical business, including product approvals, clinical milestones, financing activities, and governance matters.
Crinetics uses Form 8-K to report significant events. Recent 8-K filings have addressed topics such as U.S. FDA approval of PALSONIFY™ (paltusotine) for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, research and development updates tied to major medical meetings, and financial results for specific reporting periods. Other 8-Ks describe executive transitions, including changes in senior medical leadership and related transition and advisory agreements, with details on severance, advisory compensation, and equity award treatment.
Crinetics also files 8-Ks in connection with its capital markets activity, such as underwritten public offerings of common stock under an automatically effective shelf registration statement. These filings typically outline the size of the offering, use of proceeds—such as funding commercialization of PALSONIFY, research and development of product candidates, and general corporate purposes—and the involvement of underwriters.
In addition to 8-Ks, investors can expect to find annual reports on Form 10-K and quarterly reports on Form 10-Q in the broader SEC record, which provide more comprehensive discussions of Crinetics’ endocrine and endocrine-related tumor programs, risk factors, and financial statements. Form 4 filings, when present, disclose insider transactions in CRNX equity, offering visibility into trading by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify information about product approvals, clinical trial progress for candidates such as atumelnant and CRN09682, equity offerings, and leadership changes. Real-time updates from EDGAR, combined with simplified explanations of complex sections in 10-K and 10-Q reports, make this page a practical resource for reviewing Crinetics’ regulatory history and ongoing disclosure obligations.
Crinetics Pharmaceuticals, Inc. reported a leadership title change for one of its senior executives. Effective January 2, 2026, Jeff Knight’s role was updated from Chief Operating Officer to Chief Development and Operating Officer. The board of directors approved this change on January 20, 2026, to better reflect his existing responsibilities and scope of duties.
The company stated that there were no changes to Mr. Knight’s compensation arrangements in connection with this new title. Crinetics also confirmed that there are no arrangements or understandings with any other person related to his selection for this role, no family relationships with any director or executive officer, and no reportable related party transactions involving him. His business experience is described in the company’s 2025 proxy statement, which is incorporated by reference.
Crinetics Pharmaceuticals reported preliminary and unaudited fourth-quarter 2025 net product revenue from PALSONIFY (paltusotine) of over $5.0 million for the three months ended December 31, 2025. This early revenue snapshot reflects sales of its commercial product but may change once full year-end financial closing procedures, management review and internal control processes are completed.
The company also provided a business update at the 44th annual J.P. Morgan Healthcare Conference, using a corporate slide deck furnished as an exhibit. All of this information is being furnished rather than filed under securities laws, and Crinetics emphasized that forward-looking statements about its products, development timelines, market potential and cash runway are subject to significant risks and uncertainties.
Crinetics Pharmaceuticals’ Chief Commercial Officer, Isabel Kalofonos, reported routine insider transactions. On January 5, 2026, she exercised a stock option for 2,500 shares of common stock at an exercise price of $40.59 per share, converting derivative securities into common stock. That same day, she sold 2,500 shares of common stock in an open‑market transaction at $55.00 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 7, 2025.
Following these transactions, Kalofonos directly beneficially owned 834 shares of common stock, which include shares acquired under the company’s employee stock purchase plan, and held 97,500 stock options after the reported option exercise.
Crinetics Pharmaceuticals, Inc. entered into an underwriting agreement to issue and sell 7,620,000 shares of its common stock at a public offering price of $45.95 per share, with underwriters purchasing at $43.42275 per share. The company also granted the underwriters a 30-day option to buy up to 1,143,000 additional shares.
The company expects net proceeds of approximately $330.2 million from the offering, or approximately $379.8 million if the option is exercised in full, after underwriting discounts, commissions and estimated expenses. The offering, made under an effective shelf registration statement on Form S-3ASR, is expected to close on January 8, 2026, subject to customary closing conditions.
Crinetics Pharmaceuticals is raising equity capital by offering 7,620,000 shares of common stock at $45.95 per share. The gross proceeds are $350,139,000, with underwriting discounts and commissions of $19,257,645, resulting in estimated net proceeds of about $330.2 million, or $379.8 million if underwriters fully exercise their 1,143,000-share option. The company plans to use the cash, together with existing funds, to support the commercial launch of PALSONIFY, advance research and development across its endocrine-focused pipeline, and for general corporate purposes, including possible future in-licensing or acquisitions.
As of September 30, 2025, Crinetics had 94,548,323 shares outstanding. The company reports preliminary, unaudited net product revenue from PALSONIFY of more than $5.0 million for the quarter ended December 31, 2025 and estimates it held approximately $1.0 billion in cash, cash equivalents and investment securities as of that date. Based on the $45.95 offering price, new investors face immediate dilution of $32.22 per share, as net tangible book value is expected to rise from $11.34 to $13.73 per share after the offering.
Crinetics Pharmaceuticals, Inc. reported that Dana Pizzuti, M.D. will step down as Chief Medical and Development Officer effective December 31, 2025. Under a Transition and Separation Agreement, she will serve as a Strategic Regulatory and Development Advisor from January 1, 2026 through up to March 31, 2026. She will receive $577,000 in cash severance, eligibility for a 2025 annual bonus and a prorated 2026 bonus, up to $15,000 of legal fee reimbursement, up to 12 months of COBRA premium reimbursements, and up to $6,500 for a board training course.
Crinetics and Dr. Pizzuti also entered into an Advisor Agreement under which she will provide 10–20 hours per month of services from April 1, 2026 through up to March 30, 2028 for $600 per hour plus expense reimbursement. Certain existing equity awards will continue to vest during this advisory period, with additional vesting protections upon a Change in Control if specified conditions are met. Vested stock options may remain exercisable for up to three years after advisory service ends, subject to a ten-year maximum term.
Crinetics Pharmaceuticals (CRNX) reported Q3 2025 results and its first FDA approval. The FDA approved PALSONIFY (paltusotine) on September 25, 2025 for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. The quarter did not include product sales.
Revenue was $143 thousand, primarily from a Japan license. Operating expenses rose with commercialization and pipeline spend: research and development $90.5 million and selling, general and administrative $52.3 million. Net loss was $130.1 million (basic and diluted loss per share $1.38), compared with a $76.8 million loss a year ago. Other income was $12.5 million, reflecting interest on investments.
Cash, cash equivalents and investment securities totaled $1.09 billion as of September 30, 2025, and management believes this is sufficient for at least 12 months. The company advanced atumelnant in CAH and ADCS and prepared an SST2-targeted NDC (CRN09682) Phase 1/2 start. Shares outstanding were 94,891,840 as of October 28, 2025.
Crinetics Pharmaceuticals submitted a current report to note that it has released financial results for the period ended September 30, 2025. The company issued a press release on November 6, 2025 summarizing its operations and financial condition for that period, and that release is included as an exhibit to this report. The company also clarifies that the information in this report and the attached press release is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions.
Crinetics Pharmaceuticals (CRNX) reported an insider transaction by its Chief Medical and Development Officer. On November 3, 2025, the officer exercised 5,000 stock options at an exercise price of $16.89 per share and, on the same date, sold 4,900 shares at a volume‑weighted average price of $42.65 (price range $42.14–$43.09) and 100 shares at $43.27.
The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on May 21, 2025. Following the transactions, the officer directly beneficially owned 66,270 shares of common stock. Derivative securities beneficially owned following the transactions were 74,042 stock options. The option grant vests 25% on September 30, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued employment.
Crinetics Pharmaceuticals (CRNX) reporting person Dana Pizzuti executed option exercises and open-market sales on 10/01/2025. The Form 4 shows a stock option exercise for 5,000 shares at an exercise price of $16.89, creating 5,000 underlying shares. The same day, 5,000 shares were sold in open-market transactions under a Rule 10b5-1 trading plan at a volume-weighted average price of $41.81 (range $41.34–$42.16). Following the reported transactions, the reporting person directly owned 66,270 shares. The filer corrected a prior Form 4 that had misstated post-transaction ownership as 96,270 shares; the correction clarifies the true direct ownership.